Bone mineral content in patients with congenital generalized lipodystrophy is unaffected by metreleptin replacement therapy.

ABSTRACT:

Context

Leptin alters bone and mineral metabolism in rodents, but this has not been verified in humans. PATIENTS with congenital generalized lipodystrophy (CGL) have low leptin due to deficient adipose mass and serve as models of leptin deficiency and replacement.

Objective

To study the effects of recombinant human methionyl leptin (metreleptin) on bone mineral content (BMC) and mineral metabolism.

Design and setting

An open-label nonrandomized study at the National Institutes of Health.

Patients

Thirty-one patients with CGL (ages 4.3 to 46.7 y).

Intervention

Metreleptin (0.06 to 0.24 mg/kg/d) for 6 months to 11 years.

Outcome measures

BMC was assessed by dual-energy x-ray absorptiometry. SD scores (SDS) for BMC were calculated based on height, ra

SUBMITTER: Christensen JD 

PROVIDER: S-EPMC4121033 | biostudies-literature | 2014 Aug

REPOSITORIES: biostudies-literature